BAM
BEAM icon

Blueshift Asset Management’s Beam Therapeutics BEAM Stock Holding History

Blueshift Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,609
Closed -$689K – 919
2021
Q1 		$689K Buy
+8,609
New +$819K 0.07% 373

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blueshift Asset Management's BEAM Position: Q2 2021 in Review

Blueshift Asset Management sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 8,609 shares — an estimated $689K sold.

Blueshift Asset Management first reported a position in BEAM in Q1 2021 and held it in 1 quarter. The position peaked at $689K in Q1 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Blueshift Asset Management reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 8,609 Beam Therapeutics shares in Q2 2021, an estimated $689K.
  • Blueshift Asset Management first reported a position in Beam Therapeutics in Q1 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Beam Therapeutics position peaked at $689K in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Blueshift Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.